The purpose of this non-interventional study is to identify participants with urothelial cancer (UC) and selected fibroblast growth factor receptor (FGFR) aberrations through molecular testing of their archival tumor tissue.
Study Type
OBSERVATIONAL
Enrollment
3,679
Percentage of participants with UC and selected FGFR aberrations will be assessed through molecular testing of their archival tumor tissue.
Percentage of Participants with Selected Fibroblast Growth Factor Receptor (FGFR) Gene Aberrations
Percentage of participants with selected FGFR gene aberrations will be assessed through molecular testing of their archival tumor tissue.
Time frame: Up to 3.9 years
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Arizona Oncology Associates, PC - HOPE
Tucson, Arizona, United States
Rocky Mountain Cancer Centers
Denver, Colorado, United States
Medical Oncology Hematology Consultants, PA
Newark, Delaware, United States
Affiliated Oncologists, LLC
Chicago Ridge, Illinois, United States
Maryland Oncology Hematology, PA
Brandywine, Maryland, United States
Minnesota Oncology Hematology, P.A.
Minneapolis, Minnesota, United States
New York Oncology Hematology
Albany, New York, United States
Broome Oncology
Johnson City, New York, United States
Oncology Hematology Care
Cincinnati, Ohio, United States
Willamette Valley Cancer Institute and Research Center
Eugene, Oregon, United States
...and 189 more locations